FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
To clarify terminology, BCG-unresponsive disease includes both BCG-refractory and BCG-relapse populations. BCG-refractory refers to the presence of persistent high-grade cancer 6 months after the start of induction therapy or cancers that have progressed by either stage or grade 3 months after the initiation of induction therapy.3 BCG-relapse refers to patients with recurrence after achieving a ≥6 month disease-free interval after treatment.3 The standard of care for these patients generally remains radical cystectomy. Intravesicular valrubicin is the only regulatory approved option for BCG-refractory carcinoma in-situ and for those who do not find cystectomy to be a suitable option. Yet results are generally poor, with a 12-month disease free rate at only 16%.3 As a result, new therapeutics are needed.
Current trials for the BCG-unresponsive disease state have a strong focus on testing many of the newer immune-oncology agents. This includes moving the PD-1/PD-L1 antibodies already FDA approved for metastatic urothelial carcinoma earlier in the disease course. For instance, atezolizumab, pembrolizumab, nivolumab, and durvalumab are all being studied either alone or in combination with other agents. Please see below for more details on some actively accruing trials with PD-1/PD-L1 therapy in the BCG-unresponsive disease state.
Immuno-Oncology Trials for Patients with BCG-Unresponsive Urothelial Cancer
- Atezolizumab (NCT02844816)
- Pembrolizumab (Intravesicular) + BCG (NCT02808143)
- Pembrolizumab – KEYNOTE-057 (NCT02625961)
- Nivolumab +/- BMS-986205 (IDO-1 inhibitor) +/- BCG (NCT03519256)
- Durvalumab or Durvalumab + BCG or Durvalumab + radiation (NCT03317158)
- Durvaluamb and Vicinium (antibody drug conjugate to EPCAM) (NCT03258593)
1. Kaufman DS et al. Lancet 2009; 374:239-49.
2. Packiam VT et al. Cancer 2017; 123:390-400.
3. Kamat AM et al. Nat Rev Urol 2017; 14:244-55.
Written by: Evan Yu, MD